The latest on the scene: retatrutide , a so-called "triple-agonist" that targets GLP-1, GIP, and glucagon receptors
Even more recently completed trials have struggled with diverse enrollmenta Phase 2 trial of crenezumab in Alzheimers disease with 360 participants across 83 sites in 6 countries reported 97.5 percent of participants being white, and only 2.8 percent of all participants being Hispanic, for example (however, women consisted of 55.3 percent of all participants)
No competing UK vendor we have surveyed currently publishes this reconstitution-error argument in product copy [original observation, 2026]
Combination therapies like CagriSema promise even greater efficacy
Commercial/vendor material
18Kathawala M, Hirschfield GM